Dr. Ward is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4350 Malsbary Rd
Cincinnati, OH 45242Phone+1 513-751-2273Fax+1 513-792-5844- Is this information wrong?
Summary
- I am a board certified medical oncologist specializing in solid tumor oncology. I am a clinical investigator specializing in cellular therapies for solid tumors. I am the director of clinical research for OHC.
Education & Training
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2000 - 2002
- Ohio State University HospitalResidency, Internal Medicine, 1997 - 2000
- Ohio State University College of MedicineClass of 1997
Certifications & Licensure
- OH State Medical License 1998 - 2025
- KY State Medical License 2003 - 2020
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Top MD Consumers Checkbook
Clinical Trials
- Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
- A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
- Join now to see all
Publications & Presentations
PubMed
- AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.Ward, P. J., Nolan-Stevaux, O., Li, C., Liang, L., Zhan, J., Estrada, J., Osgood, T., Li, F., Zhang, H., Case, R., Murawsky, C., Estes, B., Moore, G., Bernett, M., Muc...> ;Cancer Discovery. 2024 Jan 12
- 2 citationsSAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.Ward, P. J., Shazer, R. L., Shazer, R. L., He, K., H Borghaei, F de Marinis, D Dumoulin, C Reynolds, W S M E Theelen, I Percent, V Gutierrez Calderon, M L Johnson, A M...> ;Annals of Oncology. 2024 Jan 1
- Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.David M Waterhouse, Patrick Ward, David R Drosick, Caleb Burdette, Daniel Davies, Molly A Mendenhall> ;JCO Oncology Practice. 2023 Nov 1
- Join now to see all
Press Mentions
- Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024
Professional Memberships
- Member
Hospital Affiliations
- The Jewish Hospital - Mercy HealthCincinnati, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: